Berlin - Delayed Quote EUR

Legend Biotech Corp (9LB.BE)

25.40

0.00

(0.00%)

At close: May 30 at 9:52:09 PM GMT+2

Exploring High Growth Tech Stocks In The US This May 2025

Over the last 7 days, the United States market has experienced a 1.4% drop, yet it remains up by 11% over the past year with earnings projected to grow by 14% annually. In such a dynamic environment, identifying high growth tech stocks requires evaluating their potential for innovation and scalability amidst these fluctuating market conditions.

Simply Wall St. 9 days ago

BILI

BLBLF

CRWV
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® infusion New data at ASCO from the CARTITUDE-4 study to showcase improved progression-free survival and overall survival with CARVYKTI® versus standard of care (SOC) in key subgroups Preliminary results from ongoing Phase 1 dose-escalation studies of LB2102 in lung cancers and LB1908 in gastroesophag

GlobeNewswire 9 days ago

LEGN
Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. During the webcast, Ying Huang, Ph.D., Chief Executive Officer, and Mythili Koneru, M.D., Ph.D., Chief Medical Officer, will host expert clinicians as they review th

GlobeNewswire 13 days ago

LEGN
Legend Biotech Shares Have 'Meaningful Upside' With Continued Execution, RBC Says

Legend Biotech (LEGN) shares are likely trading at or near their fundamental floor, with meaningful

PREMIUM
MT Newswires 16 days ago

LEGN
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension

Stock futures are mixed, signaling a potential pause following Monday’s rally driven by optimism over a temporary U.S.-China trade deal. In corporate news, UnitedHealth Group shares plunged 10% after CEO Andrew Witty stepped down, with former CEO Stephen Hemsley stepping in. The company also suspended its outlook due to rising medical costs. Bitcoin has regained value above $103,800, aligning with Coinbase’s rise after inclusion into the S&P 500. In pre-market trading, S&P 500 futures were fla

TipRanks 18 days ago

UA

UAA

UNH
Legend Biotech Corp (LEGN) Q1 2025 Earnings Call Highlights: Record Growth in CARVYKTI Sales ...

Legend Biotech Corp (LEGN) reports a 135% increase in CARVYKTI sales, strong cash reserves, and outlines plans for operational break-even by 2025.

GuruFocus.com 18 days ago

LEGN
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $369 millionOver 6,000 patients treated to dateInitiated CARVYKTI® clinical production at the Tech Lane facilityReceived positive CHMP opinion to add statistically significant improvement in overall survival from CARTITUDE-4 study to CARVYKTI® labelAustralia’s TGA approved CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.0 billion, as of March 31

GlobeNewswire 19 days ago

LEGN
What Makes Legend Biotech (LEGN) a New Buy Stock

Legend Biotech (LEGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 30 days ago

LEGN
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet

The consensus price target hints at a 135.2% upside potential for Legend Biotech (LEGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 30 days ago

LEGN
Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

SOMERSET, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, May 13, 2025, to review first-quarter 2025 results. During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter. Investors and other interested parties may join the live audio webcast of the call via this weblink. A repl

GlobeNewswire last month

LEGN
Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are Buying

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Legend Biotech Corporation (NASDAQ:LEGN) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]

Insider Monkey last month

LEGN
Exploring US High Growth Tech Stocks

Over the last 7 days, the United States market has experienced a 3.0% drop, although it has risen by 4.6% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks requires careful consideration of their innovation potential and ability to capitalize on emerging trends within a dynamic market environment.

Simply Wall St. last month

LEGN

TGTX

NFLX
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks last month

LEGN

BMRN
Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?

Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks last month

LEGN
Biotech stocks slide as Marks resignation seen being negative for sector

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

TipRanks last month

GLPG

GLPGF

PTCT
Legend Biotech Full Year 2024 Earnings: Beats Expectations

Legend Biotech ( NASDAQ:LEGN ) Full Year 2024 Results Key Financial Results Revenue: US$627.2m (up 120% from FY 2023...

Simply Wall St. 2 months ago

LEGN
Legend Biotech Corp (LEGN) Q4 2024 Earnings Call Highlights: Record CARVYKTI Sales and ...

Legend Biotech Corp (LEGN) reports a 110% increase in CARVYKTI sales, outlines expansion strategies, and anticipates profitability by 2026.

GuruFocus.com 2 months ago

LEGN
Compared to Estimates, Legend Biotech (LEGN) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 2 months ago

LEGN
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CARVYKTI® at a Novartis production facilitySpain's national health system approved reimbursement for CARVYKTI® in second-line plus settings for multiple myeloma patientsCash and cash equivalents, and time deposits of $1.1 billion, as of December 31, 2024, which Legend Biotech believes will provide fin

GlobeNewswire 2 months ago

LEGN

Performance Overview

Return	9LB.BE	MSCI WORLD (^990100-USD-STRD)
YTD	-19.62%	+4.20%
1-Year	-33.51%	+12.14%
3-Year	-35.20%	+39.46%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Legend Biotech Corp (9LB.BE)

Exploring High Growth Tech Stocks In The US This May 2025

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Legend Biotech Shares Have 'Meaningful Upside' With Continued Execution, RBC Says

Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension

Legend Biotech Corp (LEGN) Q1 2025 Earnings Call Highlights: Record Growth in CARVYKTI Sales ...

Legend Biotech Reports First Quarter 2025 Results and Recent Highlights

What Makes Legend Biotech (LEGN) a New Buy Stock

Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet

Legend Biotech to Host Investor Conference Call on First Quarter 2025 Results

Legend Biotech Corporation (LEGN): Among Takeover Rumors Hedge Funds Are Buying

Exploring US High Growth Tech Stocks

Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Pacira (PCRX) Surges 14.7%: Is This an Indication of Further Gains?

Biotech stocks slide as Marks resignation seen being negative for sector

Legend Biotech Full Year 2024 Earnings: Beats Expectations

Legend Biotech Corp (LEGN) Q4 2024 Earnings Call Highlights: Record CARVYKTI Sales and ...

Compared to Estimates, Legend Biotech (LEGN) Q4 Earnings: A Look at Key Metrics

Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights

Performance Overview